Colony stimulating factor (CSF-1) and its receptor (CSF-1R, product of c-fms proto-oncogene) were initially implicated as essential for normal monocyte development as well as for trophoblastic implantation. However, studies have demonstrated that CSF-1 and CSF-1R have additional roles in mammary gland development during pregnancy and lactation. This apparent role for CSF-1/CSF-1R in normal mammary gland development is very intriguing because this receptor/ligand pair has also been found to be important in the biology of breast cancer in which abnormal expression of CSF-1 and its receptor correlates with tumor cell invasiveness and adverse clinical prognosis. Recent findings also implicate tumor-produced CSF-1 in promotion of bone metastasis in breast cancer, and a certain membrane-associated form of CSF-1 appears to induce immunity against tumors. This review aims to summarize recent findings on the role of CSF-1 and its receptor in normal and neoplastic mammary development that may elucidate potential relationships of growth factor–induced biological changes in the breast during pregnancy and tumor progression.
RothP, StanleyER. The biology of CSF-1 and its receptor. Curr Top Microbiol Immunol181: 141–167, 1993.
3.
StanleyER, BergKL, EinsteinDB, LeePS, PixleyFJ, WangY, YeungYG. Biology and action of colony-stimulating factor-1. Mol Reprod Dev46: 4–10, 1997.
4.
HeisterkampN, GroffenJ, StephensonJr.. Isolation of v-fms and its human cellular homologue. Virology126: 248–258, 1983.
5.
RettenmeierCW, ChenJH, RousselMF, SherrCJ. The product of the c-fms proto-oncogene: a glycoprotein with associated tyrosine kinase activity. Science228: 320–322, 1985.
6.
SherrCJ. The fms oncogene. Biochim Biophys Acta948: 225–243, 1988.
7.
RohrschneiderLR, BouretteRP, LioubinMN, AlgatePA, MylesGM, CarlbergK. Growth and differentiation signals regulated by the M-CSF receptor. Mol Reprod Dev46: 96–103, 1997.
8.
HamiltonJA. CSF-1 signal transduction. J Leukoc Biol62: 145–155, 1997.
9.
WarrenMK, RalphP. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor and colony-stimulating activity. J Immunol137: 2281–2285, 1986.
10.
WangJM, GriffinJD, RambaldiA, ChenZG, MantovaniA. Induction of monocyte migration by recombinant macrophage colony stimulating factor. J Immunol141: 575–579, 1988.
11.
PollardJW, BartocciA, ArceciR, OrlovskyA, LadnerMB, StanleyER. Apparent role of the macrophage growth factor CSF-1 in placental development. Nature330: 484–486, 1987.
12.
DaiterE, PampferS, YeungYG, BaradD, StanleyER, PollardJW. Expression of colony-stimulating factor-1 in the human uterus and placenta. J Clin Endocrinol Metab74: 850–858, 1992.
13.
DaiterE, PollardJW. Colony stimulating factor-1 (CSF-1) in pregnancy. Reprod Med Rev1: 83–87, 1992.
14.
PollardJW. Role of colony-stimulating factor-1 in reproduction and development. Mol Reprod Dev46: 54–61, 1997.
15.
PollardJW, HenninghausenL. Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci USA91: 9312–9316, 1994.
16.
SapiE, FlickMB, RodovS, CarterD, KacinskiBM. Expression of CSF-1 and CSF-1 receptor by normal lactating mammary epithelial cell. J Soc Gynecol Invest5: 94–101, 1998.
17.
KacinskiBM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Rep Dev46: 71–74, 1997.
18.
RussoJ, RussoIH. Development of the human mammary gland. In: NevilleM, DanielC, Eds. The Mammary Gland, Development, Regulation and Function. New-York-London: Plenum Publishing Corp, pp 67–93, 1987.
TopperYJ, FreemanTCS. Multiple hormone interactions in the development biology of the mammary gland. Physiol Rev60: 1049–1094, 1980.
21.
VonderhaarBK, ZiskaSE. Hormonal regulation of milk protein gene expression. Annu Rev Physiol51: 641–652, 1989.
22.
HaraT, IrieK, SaitoS, IchijoM, YamadaM, YanaiN, MiyazakiS. Identification of macrophage colony-stimulating factor in human milk and mammary gland epithelial cells. Pediatr Res37: 437–443, 1995.
23.
Gouon-EvansV, RothenbergME, PollardJW. Postnatal mammary gland development requires macrophages and eosinophils. Development127: 2269–2282, 2000.
24.
RyanGR, DaiXM, DominguezMG, TongW, ChuanF, ChisholmO, RussellRG, PollardJW, StanleyER. Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood98: 74–84, 2001.
25.
Flidel-RimonO, RothP. Effects of milk-bome colony stimulating factor-1 on circulating growth factor levels in the newborn infant. J Pediatr131: 748–750, 1997.
26.
KacinskiBM, ScataKA, CarterD, YeeLD, SapiE, KingBL, ChambersSK, JonesMA, PirroMH, StanleyER, RohrschneiderLR. FMS (CSF-1R) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene6: 941–952, 1991.
27.
BartocciA, PollardJW, StanleyER. Regulation of colony stimulating factor 1 during pregnancy. J Exp Med164: 956–961, 1986.
28.
ArceciRJ, PampferS, PollardJW. Expression of CSF-1 c-fms and SF c-kit mRNA during preimplantation mouse development. Dev Biol151: 1–8, 1992.
29.
PampferS, DaiterE, BaradD, PollardJW. Expression of colony stimulating factor receptor (the c-fms proto-oncogene product) in the human uterus and placenta. Biol Reprod46: 48–57, 1992.
30.
SapiE, FlickMB, TartaroK, KimS, RakhlinY, RodovS, KacinskiBM. Effect of all-trans-retinoic acid on c-fms proto-oncogene [colony-stimulating factor 1 (CSF-1) receptor] expression and CSF-1-induced invasion and anchorage-independent growth of human breast carcinoma cells. Cancer Res59: 5578–5585, 1999.
31.
SapiE, FlickMB, Gilmore-HebertM, RodovS, KacinskiBM. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene10: 529–542, 1995.
32.
FlickMB, SapiE, KacinskiBM. Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element. J Cell Biochem85: 10–23, 2002.
33.
HynesNE, TavernaD, HarwetzIM, CiardielloF, SalomonDS, YamamotoT, GronerB. Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the β-casein gene in mouse mammary epithelial cells. Mol Cell Biol10: 4027–4034, 1990.
34.
SapiE, FlickMB, RodovS, Gilmore-HebertM, KelleyM, RockwellS, KacinskiBM. Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res56: 5704–5712, 1996.
HoriguchiJ, SaribanE, KufeD. Transcriptional and post-transcription regulation of CSF-1 gene expression in human monocytes. Mol Cell Biol8: 3951–3954, 1988.
37.
SaterRA, CripeLD, TaylorJD, NiedelJE. Complex regulation of macrophage colony-stimulating factor in the HL-60 promyelocytic cell lines. J Immunol147: 633–637, 1991.
38.
DaiXM, RyanGR, HapelAJ, DominguezMG, RussellRG, KappS, SylvestreV, StanleyER. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood99: 111–120, 2002.
39.
Van NguyenA, PollardJW. Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. Dev Biol247: 11–25, 2002.
40.
KirchheimerJC, RemoldHG. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol143: 2634–2639, 1989.
SilbersteinGB, FlandersKC, RobertsAB, DanielCW. Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev Biol152: 354–362, 1992.
43.
SlamonDJ, deKernionJB, VermaIM, ClineMJ. Expression of cellular oncogenes in human malignancies. Science224: 64–66, 1984.
44.
HoriguchiJ, ShermanML, Sampson-JohannesA, WeberBL, KufeDW. CSF-1 and c-fms gene expression in human carcinoma cell lines. Biochem Biophys Res Commun157: 395–401, 1988.
45.
RamakrishnanS, XuFJ, BrandtSJ, NiedelJE, BastRC, BrownEL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest83: 921–926, 1989.
46.
KacinskiBM, CarterD, MittalK, YeeLD, ScataKA, DonofrioL, ChambersSK, WangK-I, Yang-FengT, RohrschneiderLR, RothwellV. Ovarian adenocarcinomas express fms-complementary transcripts and Fms antigen, often with co-expression of CSF-1. Am J Pathol137: 135–147, 1990.
47.
BaiocchiG, KavanaghJJ, TalpazM, WhartonJT, GuttermanJU, KurrockR. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer67: 990–996, 1991.
48.
TangRP, BeuvonF, OjedaM, MosseriV, PouillartP, SchollS. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells. M-CSF mediated recruitment of tumour infiltrating monocytes. J Cell Biochem50: 350–356, 1992.
49.
KommossF, WolfleJ, BauknechtT, PfistererJ, Kiechle-SchwartzM, PfleidererA, SauerbreiW, KiehlR, KacinskiBM. Coexpression of M-CSF transcript and protein, FMS (M-CSF receptor) transcript and protein, and steroid receptor content in adenocarcinomas of the ovary. J Pathol174: 111–119, 1994.
50.
KacinskiBM, CarterD, MittalK, KohornEI, BloodgoodRS, DonahueJ, DonofrioL, EdwardsR, SchwartzPE, ChambersJT, ChambersSK. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radiat Oncol Biol Phys15: 823–829, 1988.
51.
KacinskiBM, CarterD, KohornEI, MittalK, BloodgoodRS, DonahueJ, KramerCA, FischerD, EdwardsR, ChambersSK, ChambersJT, SchwartzPE. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. Yale J Biol Med62: 379–392, 1989.
52.
IdeH, SeligsonDB, MemarzadehS, XinL, HorvathS, DubeyP, FlickMB, KacinskiBM, PalotieA, WitteON. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci USA29;99: 14404–14409, 2002.
53.
MaherMG, SapiE, TurnerBC, GumbsA, PerottaPL, CarterD, KacinskiBM, HafftyBG. Prognostic significance of colony stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res4: 1851–1856, 1998.
54.
FlickMB, SapiE, PerottaPL, MaherGM, HalabanR, CarterD, KacinskiBM. Recognition of activated CSF-1R in breast carcinomas by tyrosine 723 phosphospecific antibody. Oncogene14: 2553–2561, 1997.
55.
ChambersSK, KacinskiBM, IvinsCM, CarcangiuML. Over-expression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res3: 999–1007, 1997.
56.
TangR, KacinskiBM, ValidireP, BeuvonF, SastreX, BenoitP, de la RochefordiereA, MosseriV, PouillartP, SchollS. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoieitic growth factor release by tumor cells?J Cell Biochem45: 1–10, 1990.
57.
SchollSM, MosseriV, TangR, BeuvonF, PaludC, LidereauR, PouillartP. Expression of colony-stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells. Induction of urokinase production via this pathway? Ann NY Acad Sci698: 131–135, 1993.
58.
SchollSM, CrockerP, TangR, PouillartP, PollardJW. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis. Mol Carcinogen7: 207–211, 1993.
59.
KacinskiBM. The macrophage colony stimulating factor CSF-1, an auto- and paracrine tumor cytokine, is also a circulating “tumor marker” in patients with ovarian, endometrial, and pulmonary neoplasms. In: DinarelloCA, Ed. The Physiological and Pathological Effects of Cytokines. New York: Wiley-Liss, Prog Leuk Biol, Vol Part B 10: pp 393–400, 1990.
60.
KacinskiBM, ChambersSK, StanleyER, CarterDC, TsengP, ScataKA, ChangDH-Y, PirroMH, NguyenJT, ArizaA, RohrschneiderLR, RothwellV. The cytokine CSF-1 (M-CSF), expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. Int J Radiat Oncol Biol Phys19: 619–626, 1990.
61.
PriceFV, ChambersSK, ChamberJT, CarcangiuML, SchwartzPE, KohornEI, StanleyER, KacinskiBM. Colony stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol168: 520–527, 1993.
62.
HakalaA, KacinskiBM, StanleyER, KohornE, PuistolaU, RisteliJ, RisteliL, TomasC, KauppilaA. Macrophage colony stimulating factor I (CSF-1), a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA-125 and aminoterminal propeptide of type III procollagen. Am J Obstet Gynecol173: 112–119, 1995.
63.
YeeLD, LiuL. The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells. Anticancer Res20: 4379–4383, 2000.
64.
MancinoAT, KlimbergVS, YamamotoM, ManolagasSC, AbeE. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res100: 18–24, 2001.
65.
Van der PluijmG, SijmonsB, VloedgravenH, DeckersM, PapapoulosS, LowikC. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res16: 1077–1091, 2001.
66.
McDermottRS, DeneuxL, MosseriV, VedrenneJ, CloughK, FourquetA, RodriguezJ, CossetJM, SastreX, BeuzebocP, PouillartP, SchollSM. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw13: 121–127, 2002.
67.
SchwartzFG, SchwartingR. Clinical application of tissue and serum markers in breast cancer. In: HanausekM, WalaszekZ, Eds. Tumor Marker Protocols. Totowa, NJ: Humana Press, pp 61–91, 1998.
68.
SchollSM, PalludC, BeuvonF, HaceneK, StanleyER, RohrschneiderLR, TangR, PouillartP, LidereauR. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst86: 120–124, 1994.
69.
NowickiA, SzenajchJ, OstrowskaG, WojtowiczA, WojtowiczK, KruszewskiAA, MaruszynskiM, AukermanSL, Wiktor-JedrejczakW. Impaired tumor growth in colony-stimulating factor (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1 dependent macrophages in formation of tumor stroma. Int J Cancer65: 112–119, 1996.
70.
McDonoughSK, LarsenS, BrodeyRS, StockND, HardyWD. A transmissible feline fibrosarcoma of viral origin. Cancer Res31: 953–956, 1971.
71.
CoussensL, van BeverenC, SmithD, ChenE, MitchellRL, IsackeCM, VermaIM, UllrichA. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature320: 277–280, 1986.
72.
RousselMF, DullTF, RettenmierCW, RalphP, UllrichA, SherrCJ. Transformation potential of the c-fms proto-oncogene (CSF-1R). Nature325: 549–552, 1987.
73.
WoolfordJ, McAuliffeA, RohrschneiderLR. Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. Cell55: 965–977, 1988.
74.
RousselMF, DowningJR, RettenmierCW, SherrCJ. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell55: 979–988, 1988.
75.
Van Daalen WettersT, HawkinsSA, RousselMF, SherrCJ. Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain. EMBO J11: 551–557, 1992.
76.
RohrschneiderLR, RothwellVM, NicolaNA. Transformation of murine fibroblasts by a retrovirus encoding the murine c-fms proto-oncogene. Oncogene4: 1015–1022, 1989.
77.
FildermanA, BrucknerA, KacinskiBM, DengM, HinesG, RemoldH. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1R-positive cancer cell lines. Cancer Res52: 3661–3666, 1992.
78.
ChambersSK, WangY, GertzRE, KacinskiBM. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res55: 1578–1585, 1995.
79.
Van der GeerP, HunterT. Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblast. EMBO J12: 5161–5172, 1993.
80.
BouretteRP, MylesGM, CarlbergK, RohrschneiderLR. Uncoupling proliferation and differentiation signals mediated by the murine macrophage-colony-stimulating factor receptor expressed in myeloid FDC-PI cells. Cell Growth Differ6: 631–645, 1994.
81.
BouretteRP, RohrschneiderLR. Early events in M-CSF receptor signaling. Growth Factors17: 155–166, 2000.
82.
FengX, TakeshitaS, NambaN, WeiS, TeitelbaumSL, RossFP. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. Endocrinology143: 4868–4874, 2002.
83.
KlugerHM, KacinskiBM, KlugerY, MironenkoO, Gilmore-HebertM, PerkinsAS, SapiE, Microarray analysis of invasive and metastatic phenotypes in a breast cancer model. Lab Invest (in press).
84.
TalkhoudRS, ChinJR, UnemoriEN, WerbZ, BissellMJ. Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development112: 439–449, 1991.
85.
ImagawaW, PedchenkoVK, HelberJ, ZhangH. Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis. J Steroid Biochem Mol Biol80: 213–230, 2002.
86.
KacinskiBM, NguyenJ, CarterD. Expression of neu antigen in normal lactating and prepartum mammary epithelial cells. J Soc Gynecol Invest2: 51–56, 1995.
87.
PlathA, EinspanierR, PetersF, SinowatzF, SchamsD. Expression of transforming growth factors alpha and beta-1 messenger RNA in the bovine mammary gland during different stages of development and lactation. J Endocrinol155: 501–511, 1997.
88.
AlfordD, Taylor-PapadimitriouJ. Cell adhesion molecules in the normal and cancerous mammary gland. J Mammary Gland Biol Neoplasia2: 207–218, 1996.
89.
RadiceGL, Ferreira-CornwellMC, RobinsonSD, RayburnH, ChodoshLA, TakeichiM, HynesRO. Precocious mammary gland development in P-cadherin-deficient mice. J Cell Biol139: 1025–1032, 1997.
90.
LiM, HuJ, HeermeierK, HenninghausenL, FurthPA. Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk production in surviving cells. Cell Growth Differ7: 3–11, 1996.
91.
ZahnowCA. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Res4: 113–121, 2002.
92.
WatsonCJ. Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia6: 115–127, 2001.
93.
KumarR, WangRA. Protein kinases in mammary gland development and cancer. Microsc Res Tech59: 49–57, 2002.
94.
OssowskiL, BiegelD, ReichE. Mammary plasminogen activator. Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell16: 929–940, 1979.
95.
DuffyMJ, ReillyD, O'sullivanC, O'higginsN. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res50: 6827–6829, 1990.
96.
LinEY, NguyenAV, RussellRG, PollardJW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med193: 727–740, 2001.
WilliamsCC, TrinhH, TranTV, DanQ, SanchezR, DelgadoC, ChenY, SippelB, JeffesEW, WepsicHT, JadusMR. Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer. Mol Ther3: 216–224, 2001.
99.
ChenY, DouglassT, JeffesEW, XuQ, WilliamsCC, ArpajirakulN, DelgadoC, KleinmanM, SanchezR, DanQ, KimRC, WepsicHT, JadusMR. Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a “paraptosis”-induced pathway that promotes systemic immunity against intracranial T9 gliomas. Blood100: 1373–1380, 2002.
100.
DanQ, TrinhH, WilliamsCC, LloydC, WepsicHT, JeffesEW, JadusMR. Dexamethasone increases the expression of membrane macrophage colony stimulating factor from retrovirally transduced tumor cells expressing macrophage colony stimulating factor. Int Immunopharmacol1: 737–748, 2001.
